KELOWNA, BC / ACCESSWIRE / Sept. 2, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the “Company” or “Lexaria”) is pleased to announce that Catherine Turkel, PharmD, PhD, a global drug delivery platform innovator, has joined its Board of Directors I am pleased toLexalia Biosciences, Inc.
Dr. Turkel said: “We look forward to working with our leadership team and board to advance DehydraTECH technology into a broad range of medicines that can be used in several important therapeutic areas.”
Dr. Turkel has over 20 years of experience as an executive in startups and mid-sized pharmaceutical/biotech companies. She was the founder and CEO of Nezee Therapeutics and served as President and Head of Research and Development at Novus Therapeutics (renamed to Eledon Pharmaceuticals – Nasdaq: ELDN). She currently serves on the independent directors of Object Pharma (privately held) and Prostate Cancer Research (a non-profit organization, member of the Translational Scientific Advisory Committee), and Dean of Chapman University School of Pharmacy, where she serves as an advisor.
Dr. Turkel has developed registration and commercial strategic plans for the Food and Drug Administration, and has worked in neuroscience, pain, cardiovascular, psychiatry, rare diseases, ophthalmology, cosmetology, urology and otolology therapeutic areas. Dr. Turkel designed and led Allergan’s (now AbbVie-NYSE: ABBV) pioneering BOTOX® Chronic Migraine Registry program, which has generated more than $1 billion in revenue.
Chris Bunka, Chairman of Lexaria’s Board of Directors, said: “Katherine’s practical development and regulatory expertise will be of increasing value to Lexalia and we look forward to working with her.”
About Lexalia Biosciences
Lexaria Bioscience Corp.’s patented drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by facilitating more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated its ability to enhance bioabsorption with cannabinoids, antivirals, PDE5 inhibitors, and more. DehydraTECH has also demonstrated the ability to more effectively deliver some drugs across the blood-brain barrier. Lexaria operates licensed in-house laboratories and worldwide he holds 27 patents and a strong intellectual property portfolio with approximately 50 patents pending. For more information, please visit www.lexariabioscience.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements. Such terms are defined under applicable securities laws. These statements “expect”, “if”, “believe”, “plan”, “estimate”, “expect”, “intend”, “could”, “could” , and may be identified by words such as “should”. Similar expressions such as will. Such forward-looking statements contained in this press release do not represent any assurance that the Company will undertake research initiatives, receive regulatory approvals or grants, or experience research or positive effects or results from research. including, but not limited to, our statements of competence; Such forward-looking statements are estimates that reflect our best judgment based on current information and are subject to a number of risks and uncertainties. There can be no assurance that the Company will actually achieve the plans, intentions or expectations disclosed in these forward-looking statements. statement. Therefore, undue reliance should not be placed on these forward-looking statements. Factors that could cause actual results to differ materially from our expectations include government regulations and regulatory approvals, managing and sustaining growth, the impact of adverse publicity, litigation, competition, scientific discoveries and patent filings. including but not limited to. and approval processes, potential adverse effects arising from testing or use of products utilizing DehydraTECH technology, our ability to maintain existing collaborations and realize their benefits, any planned R&D delays or cancellations or other reasons, and other factors that may be identified from time to time in our official announcements regarding EDGAR and our periodic filings with the Securities and Exchange Commission. We provide a link to the third party’s website only as a courtesy to our readers and assume no responsibility for the completeness, accuracy or timeliness of the information on the third party’s website. not. There is no warranty that Lexaria’s implied use, advantage, or advantage of its patented and patent-pending technology will actually be realized in any way or in part. Statements contained herein have not been evaluated by the Food and Drug Administration (FDA). Lexaria related products are not intended to diagnose, treat, cure, or prevent any disease. The forward-looking statements contained in this release speak only as of the date of this release, and the Company reserves the right to make no forward-looking statements or statements contained in this release, whether as a result of new information or otherwise. We expressly disclaim any obligation to update links to third party websites. Future events, changes in circumstances, or otherwise, except as otherwise required by law.
George Jurcic – Head of Investor Relations
Phone: 250-765-6424, ext. 202
sauce: Lexalia Biosciences, Inc.
View source version on accesswire.com: